Gregory C Ravizzini

Dr. Gregory C Ravizzini


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Journal of Urology
Verified
Journal Article
Open access
AJAshesh B. Jani
Ashesh B. Jani
GRGregory C Ravizzini
Gregory C Ravizzini
BGBenjamin A. Gartrell
Benjamin A. Gartrell
BSBarry A. Siegel
Barry A. Siegel
PTPrzemyslaw Twardowski
Przemyslaw Twardowski
KZKatherine Zukotynski
Katherine Zukotynski
SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid (rh) 18F-rhPSMA-7.3, a novel high-affinity PET radiopharmaceutical. Men with prostate cancer recurrence underwent PET/CT 50-70 minutes after intravenous administration of 296±20% MBq 18F-rhPSMA-7.3. To assess the co-primary endpoints (verified detection rate [VDR] and combined region-level positive predictive value [crPPV]), 3 blinded, independent central readers evaluated the scans. VDR is equivalent to the overall detection rate (DR) x PPV. Standard of Truth (SoT) was established for each patient using histopathology or confirmatory imaging. Statistical thresholds (lower bounds of the confidence intervals) of 36.5% and 62.5% were prespecified for VDR and crPPV, respectively. Additional endpoints included DR, VDR and crPPV in patients with histopathology SoT, and safety. The overall 18F-rhPSMA-7.3 DR among all 389 patients with an evaluable scan was 83% (majority read). Among the 366 patients (median PSA, 1.27 ng/mL) for whom a SOT (histopathology [n=69]/confirmatory imaging only [n=297]) was available, VDR ranged from 51% (95%CI, 46.1-56.6) to 54% (95%, 48.8-59.3), exceeding the prespecified statistical threshold. crPPV ranged from 46% (95%CI, 42.0-50.3%) to 60% (95%CI, 55.1-65.5%) across the readers, not meeting the threshold. In the subset of patients with histopathology SoT, the VDR and crPPV were both above the prespecified thresholds (majority read, 81% [95%CI, 69.9-89.6] and 72% [95%CI, 62.5-80.7], respectively). No significant safety concerns were identified. 18F-rhPSMA-7.3 offers a clinically meaningful VDR for localization of recurrent prostate cancer. Despite missing the co-primary endpoint of crPPV, the totality of the data support the potential clinical utility of 18F-rhPSMA-7.3.

1 October 2021 in Current Problems in Cancer
Verified
Journal Article
Closed access
MLMai Lin
Mai Lin
VPVincenzo Paolillo
Vincenzo Paolillo
DLDao B. Le
Dao B. Le
HMHomer Macapinlac
Homer Macapinlac
GRGregory C Ravizzini
Gregory C Ravizzini

13 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MAMohammed Abusalem
Mohammed Abusalem
LMLucia Martini
Lucia Martini
SSSarita Soebianto
Sarita Soebianto
LDLouis DePalatis
Louis DePalatis
GRGregory C Ravizzini
Gregory C Ravizzini
Prostate cancer (PCa) is one of the most prevalent cancer diagnoses among men in the United States and in several other developed countries. The prostate specific membrane antigen (PSMA) has been recognized as a promising molecular target in PCa, which has led to the development of specific radionuclide-based tracers for imaging and radiopharmaceuticals for PSMA targeted therapy. These compounds range from small molecule ligands to monoclonal antibodies (mAbs). Monoclonal antibodies play a crucial role in targeting cancer cell-specific antigens with a high degree of specificity while minimizing side effects to normal cells. The same mAb can often be labeled in different ways, such as with radionuclides suitable for imaging with Positron Emission Tomography (β+ positrons), Gamma Camera Scintigraphy (γ photons), or radiotherapy (β− electrons, α-emitters, or Auger electrons). Accordingly, the use of radionuclide-based PSMA-targeting compounds in molecular imaging and therapeutic applications has significantly grown in recent years. In this article, we will highlight the latest developments and prospects of radiolabeled mAbs that target PSMA for the detection and treatment of prostate cancer.

1 November 2022 in The Cancer Journal
Verified
Journal Article
Closed access
LMLucia Martiniova
Lucia Martiniova
RZRafal J. Zielinski
Rafal J. Zielinski
MLMai Lin
Mai Lin
LDLouis DePalatis
Louis DePalatis
GRGregory C Ravizzini
Gregory C Ravizzini
Antibody-drug conjugates (ADCs) are designed to deliver cytotoxic payloads to distinctive target-expressing cancer cells. Following internalization, the ADCs are routed to different compartments in the cells, where cleavage of the linker causes release of the cytotoxic cargo. With such a delivery system, more effective payloads can reach cancer cells, allowing for more efficient treatment and dosing schedule. The monoclonal antibody (mAb) component of ADC plays a crucial role in the effective targeting of cancer cell–specific antigens while minimizing binding to normal cells. Often, the same mAbs used in ADCs can be labeled instead with radionuclides suitable for positron emission tomography or gamma-camera scintigraphy. To achieve high sensitivity and specificity for imaging, radiolabeled mAbs must have high affinity for the antigen, favorable pharmacokinetic properties, and a low toxicity profile. The use of radiolabeled mAbs permits the noninvasive interrogation of specific target expression on tumor cells and assessment of tumor heterogeneity in vivo by a simple diagnostic imaging scan that may include the whole body in the field of view. With this approach, radiolabeled mAbs can serve as important imaging biomarkers to predict the optimal delivery of ADCs to tumors and be used to monitor therapy with follow-up scans. Moreover, the same mAb can then be radiolabeled with an analogous radionuclide for the delivery of β-emitters, α-particles, or Auger electrons as part of a radioimmunotherapy approach. The purpose of this review is to introduce key concepts regarding radiolabeled mAbs targeting various tumor antigens (CD20, CDH3, type I insulinlike growth factor receptor, prostate-specific membrane antigen, and human epidermal growth factor receptor 2) that are being used in the clinical setting or undergoing development.

29 June 2021 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
FWFranklin C. Wong
Franklin C. Wong
LMLucia Martiniova
Lucia Martiniova
AMAvantika Masrani
Avantika Masrani
GRGregory C Ravizzini
Gregory C Ravizzini
A 74-year-old man presenting with biochemical recurrent prostate cancer 9 months after robotic-assisted radical prostatectomy and pelvic lymphadenectomy underwent 18F-fluciclovine PET/CT for restaging to determine subsequent treatment strategy. Serum prostate-specific antigen was 0.7 ng/mL at the time of imaging. Images demonstrated foci of abnormal increased 18F-fluciclovine uptake corresponding to prominent round lymph nodes in the left axilla, some of which with fatty hila. Due to recent mRNA COVID-19 vaccination in the ipsilateral arm and the low likelihood of nodal metastases to the axilla from prostate cancer in this patient, the lymph nodes were considered to be benign, reactive to the vaccine.

4 April 2017 in Diagnostics
Verified
Journal Article
Open access
PDF file
KKKalevi Kairemo
Kalevi Kairemo
GRGregory C Ravizzini
Gregory C Ravizzini
HMHomer A. Macapinlac
Homer A. Macapinlac
VSVivek Subbiah
Vivek Subbiah
Fluorothymidine is a thymidine analog labeled with fluorine-18 fluorothymidine for positron emission tomography (18F-FLT-PET) imaging. Thymidine is a nucleic acid that is used to build DNA. Fluorine-18 fluorothymidine (18F-FLT) utilizes the same metabolic pathway as does thymidine but has a very low incidence of being incorporated into the DNA (<1%). 18F-FLT-PET could have a role in the evaluation of response to targeted therapy. We present here a pilot study where we investigated cellular metabolism and proliferation in patients with prostate cancer before and after targeted therapy. Seven patients with Stage IV prostate adenocarcinoma, candidates for targeted therapy inhibiting the hepatocyte growth factor/tyrosine-protein kinase Met (HGF/C-MET) pathway, were included in this study. The HGF/C-MET pathway is implicated in prostate cancer progression, and an evaluation of the inhibition of this pathway could be valuable. 18F-FLT was performed at baseline and within four weeks post-therapy. Tumor response was assessed semi-quantitatively and using visual response criteria. The range of SUVmax for 18F-FLT at baseline in the prostate varied from 2.5 to 4.2. This study demonstrated that 18F-FLT with positron emission tomography/computerized tomography (18F-FLT PET/CT) had only limited applications in the early response evaluation of prostate cancer. 18F-FLT PET/CT may have some utility in the assessment of response in lymph node disease. However, 18F-FLT PET/CT was not found to be useful in the evaluation of the prostate bed, metastatic skeletal disease, and liver disease.